Primary cardiac angiosarcomas are rare tumors with unfavorable prognosis. Pathogenic driver mutations are largely unknown. We therefore analyzed a collection of cases for genomic aberrations using SNP arrays and targeted next generation sequencing (tNGS) of oncogenes and tumor suppressor genes. Recurrent gains of chromosome 1q and a small region of chromosome 4 encompassing KDR and KIT were identified by SNP array analysis. Repeatedly mutated genes identified by tNGS were KDR with different nonsynonymous mutations, MLL2 with different nonsense mutations and PLCG1 with a recurrent nonsynonymous mutation (R707Q) in the highly conserved autoinhibitory SH2 domain in three of 10 cases. PLCγ1 is usually activated by Y783 phosphorylation and activates PKC and Ca2+ dependent second messengers with effects on cellular proliferation, migration and invasiveness. Ectopic expression of the PLCγ1-R707Q mutant in endothelial cells revealed reduced PLCγ1-Y783 phosphorylation with concomitant increased c-RAF/MEK/ERK1/2 phosphorylation, increased IP3 amounts and increased Ca2+ dependent calcineurin activation compared to ectopic expressed PLCγ1-wildtype. Furthermore, cofilin, whose activation is associated with actin skeleton reorganization, showed decreased phosphorylation and thus activation after expression of PLCγ1-R707Q compared to PLCγ1-wildtype. At the cellular level expression of PLCγ1-R707Q in endothelial cells had no influence on proliferation rate but increased apoptosis resistance and migration and invasiveness in in-vitro assays. Together, these findings indicate that the PLCγ1-R707Q mutation causes constitutive activation of PLCγ1 and may represent an alternative way of activation of KDR/PLCγ1 signaling beside KDR activation in angiosarcomas with implications for VEGF/KDR targeted therapies.


